Clinical and Economic Analysis of the Pharmaceutical Provision of Patients with Fractures caused by Osteoporosis

Despite the significant progress in treating patients with fractures, this pathology remains an important problem. The proximal femoral bone fractures are closely related to systemic osteoporosis and complications often cause disability, and this medical problem is associated with significant costs. Therefore, it is advisable to carry out a comprehensive statistical analysis of the osteoporotic fractures pharmacotherapy to provide guidance on the development and improvement of pharmaceutical formulary. The purpose of the work was to carry out a clinical and economic analysis of the state of pharmaceutical provision of patients with fractures caused by osteoporosis. Material and methods. We used the retrospective clinical and economic analysis based on the history of diseases in this study. Results and discussion. Retrospective clinical and economic analysis of medical appointments was carried out on the basis of 55 patient charts of inpatient clinics. We chose the charts of patients with fractures of different localization, which were treated in the traumatological department of the Emergency Medical Hospital of Chernivtsi during 2017. The total cost of the pharmacotherapy of the femoral neck fracture which is the main osteoporosis complication, was totally 259296.10 UAH. Here, the largest number of appointments belongs to the pharmacotherapeutic group "Medications affecting the digestive system and metabolism" which made up 32.93%. This group includes the subgroups "Vitamins" and "Mineral supplements". This pharmacotherapeutic group costs were 40993.50 UAH. The second most frequent appointment was the pharmacotherapeutic group "Medications affecting the musculoskeletal system", the cost of pharmacotherapy with these drugs was 61416.00 UAH. According to the statistical research results, regarding the implementation of medicinal products in this medical problem, the main part of the expenses was the drugs of the group "Antimicrobial drugs with systemic use", the second place was taken by "Medications affecting the musculoskeletal system", the third place was taken by "Antithrombotic drugs", the penultimate place was taken by calcium-containing drugs. The next task was to assess the importance of drugs that were used for osteoporosis pharmacotherapy. Microelements with vitamin D relate to the status N, the cost of which is 40.65%. Conclusion. Taking into account the high cost of treating the main complication of osteoporosis, we can assume that patients can optimize costs with the help of timely prevention with the status N drugs, namely calcium-containing drugs. Therefore, to reduce the cost of fractures treatment it is necessary to timely prevent osteoporosis by combination of calcium-containing drugs with vitamin D3.